$FOMI
FORMATION MINERALS, INC.

2023 Q3 Form 10-Q Financial Statement

#000121390023076640 Filed on September 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $335.00
YoY Change -91.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $141.9K
YoY Change
% of Gross Profit
Research & Development $6.914K
YoY Change
% of Gross Profit
Depreciation & Amortization $15.48K
YoY Change
% of Gross Profit
Operating Expenses $6.914K
YoY Change
Operating Profit -$148.8K
YoY Change -17.91%
Interest Expense $2.041K
YoY Change -4.49%
% of Operating Profit
Other Income/Expense, Net $10.16K
YoY Change
Pretax Income -$150.5K
YoY Change -16.23%
Income Tax
% Of Pretax Income
Net Earnings -$148.9K
YoY Change -16.44%
Net Earnings / Revenue -44438.21%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 56.35M shares
Diluted Shares Outstanding 5.363M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.19K
YoY Change
Cash & Equivalents $12.19K $26.96K
Short-Term Investments
Other Short-Term Assets $13.02K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.20K $39.65K
YoY Change -90.99% -90.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $25.20K $39.65K
Total Long-Term Assets $0.00 $0.00
Total Assets $25.20K $39.65K
YoY Change -90.99% -90.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $538.5K
YoY Change
Accrued Expenses $63.50K $52.00K
YoY Change -0.42% -20.87%
Deferred Revenue
YoY Change
Short-Term Debt $80.96K $82.82K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.142M $1.101M
YoY Change 27.52% 24.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.142M $1.101M
Total Long-Term Liabilities $0.00
Total Liabilities $1.142M $1.101M
YoY Change 27.52% 21.97%
SHAREHOLDERS EQUITY
Retained Earnings -$6.176M -$6.027M
YoY Change 12.39% 35.95%
Common Stock $1.084M $1.073M
YoY Change 85.02% 74.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.339M -$1.284M
YoY Change
Total Liabilities & Shareholders Equity $25.20K $39.65K
YoY Change -90.99% -90.98%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$148.9K
YoY Change -16.44%
Depreciation, Depletion And Amortization $15.48K
YoY Change
Cash From Operating Activities -$17.85K
YoY Change -88.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $329.9K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$17.85K
Cash From Investing Activities $329.9K
Cash From Financing Activities
Net Change In Cash -$14.77K
YoY Change -90.76%
FREE CASH FLOW
Cash From Operating Activities -$17.85K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Other Long Term Debt
OtherLongTermDebt
usd
CY2023Q3 dei Trading Symbol
TradingSymbol
SSTC
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-07-31
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
SENSASURE TECHNOLOGIES INC.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q3 dei Entity File Number
EntityFileNumber
001-41209
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-2406468
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
4730 S. Fort Apache Rd.
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89147
CY2023Q3 dei City Area Code
CityAreaCode
(347)
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
325-4677
CY2023Q3 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
56349183 shares
CY2023Q3 us-gaap Cash
Cash
12188 usd
CY2023Q2 us-gaap Cash
Cash
26786 usd
CY2023Q2 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
172 usd
CY2023Q3 sesu Prepayments And Other Receivables
PrepaymentsAndOtherReceivables
13015 usd
CY2023Q2 sesu Prepayments And Other Receivables
PrepaymentsAndOtherReceivables
12688 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
25203 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
39646 usd
CY2023Q3 us-gaap Assets
Assets
25203 usd
CY2023Q2 us-gaap Assets
Assets
39646 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
118543 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
105868 usd
CY2023Q3 sesu Accounts Payable And Accrued Liabilities To A Related Party
AccountsPayableAndAccruedLiabilitiesToARelatedParty
483426 usd
CY2023Q2 sesu Accounts Payable And Accrued Liabilities To A Related Party
AccountsPayableAndAccruedLiabilitiesToARelatedParty
486826 usd
CY2023Q3 sesu Demand Loan Current
DemandLoanCurrent
111720 usd
CY2023Q2 sesu Demand Loan Current
DemandLoanCurrent
113375 usd
CY2023Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
80957 usd
CY2023Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
82823 usd
CY2023Q3 sesu Amount Due To Related Parties Current
AmountDueToRelatedPartiesCurrent
347457 usd
CY2023Q2 sesu Amount Due To Related Parties Current
AmountDueToRelatedPartiesCurrent
312347 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1142103 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1101239 usd
CY2023Q3 us-gaap Liabilities
Liabilities
1142103 usd
CY2023Q2 us-gaap Liabilities
Liabilities
1101239 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
436431 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
425431 usd
CY2023Q3 sesu Shares To Be Issue
SharesToBeIssue
804000 shares
CY2023Q2 sesu Shares To Be Issue
SharesToBeIssue
804000 shares
CY2023Q3 sesu Shares To Be Issued Value
SharesToBeIssuedValue
15755 usd
CY2023Q2 sesu Shares To Be Issued Value
SharesToBeIssuedValue
15755 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4599073 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4533073 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-214484 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
-231505 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6176077 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6027209 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1339302 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-1284455 usd
CY2023Q3 us-gaap Noncontrolling Interest In Variable Interest Entity
NoncontrollingInterestInVariableInterestEntity
41601 usd
CY2023Q2 us-gaap Noncontrolling Interest In Variable Interest Entity
NoncontrollingInterestInVariableInterestEntity
42061 usd
CY2023Q3 us-gaap Statutory Accounting Practices Statutory Capital And Surplus Balance
StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
180801 usd
CY2023Q2 us-gaap Statutory Accounting Practices Statutory Capital And Surplus Balance
StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
180801 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1116900 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1061593 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25203 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39646 usd
CY2023Q3 us-gaap Revenues
Revenues
335 usd
CY2022Q3 us-gaap Revenues
Revenues
3734 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
141885 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
181268 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6914 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-148799 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-181268 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
2041 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
2137 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-150505 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-179671 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-150505 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-179671 usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1637 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1520 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-148868 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-178151 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.003
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.002
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56349183 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105723183 shares
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-150505 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-179671 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18198 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12352 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132307 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-167319 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
148868 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
178151 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-17021 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-11554 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
-1637 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
-1520 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1177 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-798 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-132307 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-167319 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1061593 usd
CY2023Q3 sesu Amortization Of Vested Share
AmortizationOfVestedShare
77000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-150505 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
18198 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1116900 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-463205 usd
CY2022Q3 sesu Subsidiary Issuance Of Shares Pursuant To Private Placement
SubsidiaryIssuanceOfSharesPursuantToPrivatePlacement
45 usd
CY2022Q3 sesu Amortization Of Vested Share
AmortizationOfVestedShare
14576 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-179671 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
12352 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-615903 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-150505 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-179671 usd
CY2023Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
77000 usd
CY2022Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
14576 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1451 usd
CY2023Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
619 usd
CY2022Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1478 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13397 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-13051 usd
CY2023Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
42876 usd
CY2022Q3 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
39738 usd
CY2022Q3 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-17443 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17851 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-155824 usd
CY2022Q3 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
45 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45 usd
CY2023Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3081 usd
CY2022Q3 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4080 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14770 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-159859 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26958 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
437177 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12188 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
277318 usd
CY2023Q3 us-gaap Nature Of Operations
NatureOfOperations
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION OF BUSINESS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SensaSure Technologies, Inc. (“SensaSure” or “Company”) was incorporated on September 8, 2020 under the laws of the State of Nevada with an authorized share capital of 250,000,000 common shares, 5,000,000 of Class A and 5,000,000 Class B preferred shares. The Company did not issue any number of common shares, Class A and Class B preferred shares before December 21, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sensa Bues AB (“Sensa Bues”) was incorporated in the Kingdom of Sweden in November 2009. Sensa Bues AB owns the core intellectual properties for the design of sample collection devices and the methodologies to collect, extract and detect the non-volatile substances presented within aerosols in exhaled breath. These aerosols, which originate from the lungs and blood, are captured using electret-based filter technologies.  This non-invasive breath-based biological sample collection and testing methodology is called ExaBreath (“EB”) technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sensa Bues AB performs medical device design and research focusing on developing and commercializing EB for disease detection, exposure monitoring, and drug metabolism.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2020, the Company completed a reverse recapitalization via a share exchange agreement with Sensa Bues AB and the shareholders who owned 270,339 common shares that represented 72.82% of the total issued and outstanding common shares in Sensa Bues AB. Under the share exchange agreement, the shareholders of Sensa Bues AB, agreed to exchange their shares of Sensa Bues AB for common shares of SensaSure at an exchange ratio of approximate 1:49.99. Pursuant to the share exchange transactions (see share exchange agreement noted above), SensaSure issued a total of 13,515,183 common shares and the then-shareholders of Sensa Bues AB hold their ownership of Sensa Bues AB through SensaSure (Note 8 (b)). Upon completion of the share exchange transaction, SensaSure became the controlling shareholder that owned 74.82% the total issued and outstanding common shares in Sensa Bues AB and parent company of Sensa Bues AB (“Subsidiary”). No goodwill or other intangible assets were recorded during the reverse capitalization. As noted earlier, this transaction has been accounted for as a reversed recapitalization, the operating results included in this discussion reflect the historical operating results of Sensa Bues AB prior to the reverse capitalization transaction.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During April 2021, the Company increased its ownership interest in Sensa Bues AB pursuant to private placements completed by Sensa Bues AB where 277,296 common shares and 93,032 common shares were issued to the Company and noncontrolling interests respectively. (Note 8 (b)).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended July 31, 2022, the Company increased its ownership interest in Sensa Bues AB pursuant to private placements completed by Sensa Bues where 2,200,000 common shares and 440 common shares were issued to the Company and noncontrolling interests respectively. (Note 8 (b)).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2023, the Company owned 93.53% (93.53% - April 30, 2023) of the total issued and outstanding common shares in Sensa Bues. On July 31, 2022, the Company owned 93.53% (74% - April 30, 2022) of the total issued and outstanding common shares in Sensa Bues AB (Note 8 (c)).</p>
CY2023Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
53868 usd
CY2020Q4 sesu Description Of Share Exchange Agreement
DescriptionOfShareExchangeAgreement
the Company completed a reverse recapitalization via a share exchange agreement with Sensa Bues AB and the shareholders who owned 270,339 common shares that represented 72.82% of the total issued and outstanding common shares in Sensa Bues AB. Under the share exchange agreement, the shareholders of Sensa Bues AB, agreed to exchange their shares of Sensa Bues AB for common shares of SensaSure at an exchange ratio of approximate 1:49.99. Pursuant to the share exchange transactions (see share exchange agreement noted above), SensaSure issued a total of 13,515,183 common shares and the then-shareholders of Sensa Bues AB hold their ownership of Sensa Bues AB through SensaSure (Note 8 (b)). Upon completion of the share exchange transaction, SensaSure became the controlling shareholder that owned 74.82% the total issued and outstanding common shares in Sensa Bues AB and parent company of Sensa Bues AB (“Subsidiary”).
CY2022Q3 sesu Common Stock Share Issued
CommonStockShareIssued
2200000 shares
CY2022Q3 sesu Common Shares Noncontrolling Interests
CommonSharesNoncontrollingInterests
440 shares
CY2023Q3 sesu Working Capital Deficiency
WorkingCapitalDeficiency
1116900 usd
CY2023Q2 sesu Working Capital Deficiency
WorkingCapitalDeficiency
1061593 usd
CY2022Q2 sesu Several Private Placements
SeveralPrivatePlacements
368200 usd
CY2021Q2 sesu Several Private Placements
SeveralPrivatePlacements
893014 usd
CY2023Q2 sesu Working Capital Loans
WorkingCapitalLoans
39979 usd
CY2021Q1 us-gaap Gas Imbalance Payable Current And Noncurrent
GasImbalancePayableCurrentAndNoncurrent
333744 usd
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
63500 usd
CY2023Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
52000 usd
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical management judgment and use of estimates</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Areas involving significant estimates and assumptions include: deferred income tax assets and related valuation allowance, accruals, stock options, principles of consolidation and reverse recapitalization and assumptions used in the going concern assessment. Actual results could differ from those estimates. These estimates are reviewed periodically, and, as adjustments become necessary, they are reported in earnings in the period in which they become known.</p>
CY2023Q3 us-gaap Effective Income Tax Rate Reconciliation Tax Settlements
EffectiveIncomeTaxRateReconciliationTaxSettlements
0.50 pure
CY2021 sesu Proceeds From Private Placement
ProceedsFromPrivatePlacement
793000 usd
CY2021 sesu Proceed From Issuance Of Common Stock
ProceedFromIssuanceOfCommonStock
12200000 shares
CY2021 sesu Issued Of Common Shares
IssuedOfCommonShares
11780000 shares
CY2023Q3 sesu Proceeds Received In Common Stock
ProceedsReceivedInCommonStock
117800 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
647900 usd
CY2021Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
27300 usd
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
420000 shares
CY2022 sesu Subscription Proceeds Received
SubscriptionProceedsReceived
420000 shares
CY2023Q3 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
55043 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
118543 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
105868 usd
CY2023Q3 us-gaap Redeemable Noncontrolling Interest Equity Fair Value
RedeemableNoncontrollingInterestEquityFairValue
27906 usd
CY2023Q3 us-gaap Redeemable Noncontrolling Interest Equity Fair Value
RedeemableNoncontrollingInterestEquityFairValue
293000 sek
CY2023Q2 us-gaap Redeemable Noncontrolling Interest Equity Fair Value
RedeemableNoncontrollingInterestEquityFairValue
28550 usd
CY2023Q2 us-gaap Redeemable Noncontrolling Interest Equity Fair Value
RedeemableNoncontrollingInterestEquityFairValue
293000 sek
CY2023Q3 us-gaap Derivative Fixed Interest Rate
DerivativeFixedInterestRate
0.20 pure
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1384 usd
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1359 usd
CY2023Q3 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
39979 usd
CY2023Q2 us-gaap Debt Default Longterm Debt Amount
DebtDefaultLongtermDebtAmount
39979 usd
CY2021Q1 sesu Aggregated Shares
AggregatedShares
3400 shares
CY2021Q1 sesu Number Of Common Shares
NumberOfCommonShares
50 shares
CY2023Q3 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
28573 usd
CY2023Q3 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
300000 sek
CY2023Q2 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
29232 usd
CY2023Q2 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
300000 sek
CY2023Q3 sesu Unsecured Bearing Interest
UnsecuredBearingInterest
0.02 pure
CY2023Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
483426 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6914 usd
CY2021Q1 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
333744 usd
CY2021Q1 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
798280 sek
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56349183 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56349183 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56349183 shares
CY2021 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
99643 usd
CY2021 sesu Common Shares To Noncontrolling Interests
CommonSharesToNoncontrollingInterests
10000 shares
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
499935 shares
CY2023Q3 us-gaap Proceeds From Customers
ProceedsFromCustomers
4999 usd
CY2023Q3 us-gaap Common Stocks Including Additional Paid In Capital Net Of Discount
CommonStocksIncludingAdditionalPaidInCapitalNetOfDiscount
94644 usd
CY2020Q4 sesu Owned Common Shares
OwnedCommonShares
270339 shares
CY2020Q4 sesu Owned Common Shares Percentage
OwnedCommonSharesPercentage
0.7282 pure
CY2020Q4 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
13515183 shares
CY2020Q4 us-gaap Accelerated Share Repurchases Cash Or Stock Settlement
AcceleratedShareRepurchasesCashOrStockSettlement
Shareholders agreed that from the Effective Date of share exchange agreement the Shareholders shall have up to 243,402 shares to sell when a trading market begins on the OTC Markets. Eighteen (18) months after the initial listing date of the shares on the NASDAQ Market, the Shareholder shall have 1,914,704 shares available to sell. Twenty-four (24) months after the initial listing date of the shares on the NASDAQ Market, the Shareholders shall have 5,744,109 shares available to sell.
CY2021 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
793000 usd
CY2021 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
12200000 shares
CY2021 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
11780000 shares
CY2021 sesu Agreement Description
AgreementDescription
The proceeds received was reflected as an increase in common stock in amount of $117,800 and additional paid-in capital in amount of $647,900 respectively. The Company recognized a subscription receivable in amount of $27,300 as well as shares to be issued at April 30, 2021. The number of shares to be issued was 420,000. The Company received the subscription proceeds subsequently to year end and issued 420,000 common shares accordingly (Note 4). The subscribers entered into lock up agreement pursuant to which (1) The Shareholders shall 1,715,800 of the shares subscribed to sell when a trading market begins on the OTC Markets; (ii) The Shareholders shall have 5,346,000 of their remaining shares available to sell Six (6) months after the initial listing date of the shares on the NASDAQ Market; (iii) The Shareholders shall have their remaining shares for trading Eighteen (18) months after the initial listing date of the shares on the NASDAQ Market; and (iv) In the event the stock does not begin trading on the NASDAQ Market within a period of Thirty-Six (36) months after the execution of the Share Exchange Agreement, the Shareholders shall have up to Thirty Percent (30%) of their remaining shares available to sell after the initial listing date of the shares on the OTC Market. The balance of the Shareholder’s shares shall be available for trading Sixty (60) months after the initial listing date of the shares on the OTC Market (the “Lock Up Period”).
CY2022 sesu Shares Available Description
SharesAvailableDescription
After the revision, the shareholders shall have 10,898,736 shares available to sell upon a trading market begins on OTC Market, 7,738,000 shares available to sell upon six months after a trading market begins on OTC Market, 4,750,000 shares available to sell upon initial listing date on the Nasdaq Market, 6,280,000 shares available to sell upon six months after initial listing date on the Nasdaq Market, 800,000 shares available to sell upon twelve months after initial listing date on the Nasdaq Market, 3,838,213 shares available to sell upon eighteen months after the initial listing date on Nasdaq Market, 6,620,863 shares available to sell upon twenty four months after the initial listing date on Nasdaq Market and the balance of the shareholders’ shares will be available to sell upon sixty months after the initial listing date on Nasdaq Market.
CY2023Q3 sesu Fair Value Of Shares Issued Amount
FairValueOfSharesIssuedAmount
502614 usd
CY2022 sesu Unvested Shares
UnvestedShares
7931000 shares
CY2022 sesu Unvested Shares
UnvestedShares
8587000 shares
CY2023Q3 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
36440 usd
CY2023Q3 us-gaap Other Expense From Real Estate Partnership Operations
OtherExpenseFromRealEstatePartnershipOperations
15950 usd
CY2023Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
20490 usd
CY2021 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
24371 shares
CY2021 us-gaap Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued
DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
360795 usd
CY2022Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
21637000 shares
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
216370 usd
CY2022 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
27950000 shares
CY2023Q3 sesu Common Shares
CommonShares
50 shares
CY2021Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
27300 usd
CY2023Q3 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
420000 shares
CY2022Q2 sesu Proceeds Received From Common Stock Issued
ProceedsReceivedFromCommonStockIssued
420000 shares
CY2022 us-gaap Payments For Repurchase Of Private Placement
PaymentsForRepurchaseOfPrivatePlacement
340900 usd
CY2022 us-gaap Accelerated Share Repurchases Initial Price Paid Per Share
AcceleratedShareRepurchasesInitialPricePaidPerShare
0.07
CY2023Q3 sesu Agreement Description
AgreementDescription
The proceeds received was reflected as an increase in common stock in amount of $48,700 and additional paid-in capital in amount of $292,200 respectively. The subscribers entered into lock up agreement and the shareholders shall have 502,584 shares available to sell upon a trading market begins on OTC Market, 356,484 shares available to sell upon six months after a trading market begins on OTC Market, 218,663 shares available to sell upon initial listing date on the Nasdaq Market, 289,278 shares available to sell upon six months after initial listing date on the Nasdaq Market, 37,012 shares available to sell upon twelve months after initial listing date on the Nasdaq Market, 176,781 shares available to sell upon eighteen months after the initial listing date on Nasdaq Market, 304,862 shares available to sell upon twenty four months after the initial listing date on Nasdaq Market and the balance of the shareholders’ shares will be available to sell upon sixty months after the initial listing date on Nasdaq Market.
CY2023Q3 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
During the year ended April 30, 2022, the Company approved the issuance of 2,118,000 shares of the common stock to several consultants and directors. The fair value of the share-based compensation was in the amount of $148,260 and was included in the general and admirative expenses as well as a credit made in common stock in amount of 21,180 and additional paid-in capital in amount of 127,080 respectively. The fair value of the shares of common stock issued was determined by using the most recent private placement price at $0.07 per share. One of the consultants is a related party individual and the share awards was 2,100,000 common shares with an amount of 147,000.During the year ended April 30, 2022, SensaSure issued 3,080,000 common stock to a consultant of the Company for services to be provided in future including completion of certain financing projects and regulatory services. The fair value of the shares of common stock issued was determined by using the most recent private placement price at $0.07 per share. At April 30, 2022 and 2023, none of these services were rendered. Accordingly, the Company has not recognized any share based compensation expense during the year.
CY2023Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
54000 shares
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3780 usd
CY2023 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
750000 shares
CY2023Q2 us-gaap Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
750000 shares
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
11975 usd
CY2022Q3 sesu Common Share
CommonShare
2200000 shares
CY2022Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
225641 usd
CY2023Q1 sesu Issuance Of Shares Of Common Stock
IssuanceOfSharesOfCommonStock
8800000 shares
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1650000 shares
CY2023 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
115500 usd
CY2023 us-gaap Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued
DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
16500 usd
CY2023Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.07
CY2021Q2 us-gaap Common Unit Issued
CommonUnitIssued
22000000 shares
CY2023 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
35500 usd
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
638000 shares
CY2022Q3 us-gaap Common Stocks Including Additional Paid In Capital
CommonStocksIncludingAdditionalPaidInCapital
6380 usd
CY2022Q3 us-gaap Common Stocks Including Additional Paid In Capital Net Of Discount
CommonStocksIncludingAdditionalPaidInCapitalNetOfDiscount
8196 usd
CY2023Q3 sesu Unvested Shares Amount
UnvestedSharesAmount
60500 usd
CY2023 sesu Unvested Common Shares
UnvestedCommonShares
3080000 shares
CY2023Q3 sesu Common Shareholders Of The Company Percentage
CommonShareholdersOfTheCompanyPercentage
0.9353 pure
CY2023Q2 sesu Common Shareholders Of The Company Percentage
CommonShareholdersOfTheCompanyPercentage
0.9353 pure
CY2022Q3 sesu Common Shareholders Of The Company Percentage
CommonShareholdersOfTheCompanyPercentage
0.9353 pure
CY2022Q2 sesu Common Shareholders Of The Company Percentage
CommonShareholdersOfTheCompanyPercentage
0.74 pure
CY2023Q3 sesu Noncontrolling Interests Percentage
NoncontrollingInterestsPercentage
0.0647 pure
CY2023Q2 sesu Noncontrolling Interests Percentage
NoncontrollingInterestsPercentage
0.0647 pure
CY2022Q3 sesu Noncontrolling Interests Percentage
NoncontrollingInterestsPercentage
0.0647 pure
CY2022Q2 sesu Noncontrolling Interests Percentage
NoncontrollingInterestsPercentage
0.26 pure
CY2023Q3 sesu Unvested Common Shares
UnvestedCommonShares
6050000 shares
CY2021Q2 us-gaap Option Contract Indexed To Equity Settlement Cash Effect Of Change In Fair Value Of Share
OptionContractIndexedToEquitySettlementCashEffectOfChangeInFairValueOfShare
usd
CY2023Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
usd
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-883768 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-883768 usd
CY2023Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
59804 usd
CY2022Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
108102 usd
CY2023Q3 sesu Subscription Receivable
SubscriptionReceivable
usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2022Q3 sesu Effect Of Dilution Of Ownership In Subsidiary Pursuant To Issuance Of Shares
EffectOfDilutionOfOwnershipInSubsidiaryPursuantToIssuanceOfShares
usd
CY2023Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2023Q3 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
usd
CY2023Q3 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022Q3 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q3 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q3 us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
usd
CY2023 us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
usd
CY2023Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
usd
CY2023 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2023Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
usd
CY2023Q3 us-gaap Other Minority Interests
OtherMinorityInterests
usd
CY2022Q3 us-gaap Other Minority Interests
OtherMinorityInterests
usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
usd
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001885336
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56349183 shares

Files In Submission

Name View Source Status
0001213900-23-076640-index-headers.html Edgar Link pending
0001213900-23-076640-index.html Edgar Link pending
0001213900-23-076640.txt Edgar Link pending
0001213900-23-076640-xbrl.zip Edgar Link pending
f10q0723ex31-1_sensasuretech.htm Edgar Link pending
f10q0723ex31-2_sensasuretech.htm Edgar Link pending
f10q0723ex32-1_sensasuretech.htm Edgar Link pending
f10q0723ex32-2_sensasuretech.htm Edgar Link pending
f10q0723_sensasuretech.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
f10q0723_sensasuretech_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sesu-20230731.xsd Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
sesu-20230731_cal.xml Edgar Link unprocessable
sesu-20230731_def.xml Edgar Link unprocessable
sesu-20230731_pre.xml Edgar Link unprocessable
sesu-20230731_lab.xml Edgar Link unprocessable